Drug Utilization Review Board

(DUR Board)

Meeting - January 14, 2009 @ 6:00 p.m.

Oklahoma Health Care Authority 4545 N. Lincoln Suite 124 Oklahoma City, Oklahoma 73105

Oklahoma Health Care Authority Board Room

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. McNeill, Chairman:

- 1. Call To Order
 - A. Roll Call Dr. Graham

Items to be presented by Dr. McNeill, Chairman:

- 2. Public Comment Forum
 - A. Acknowledgment of Speakers and Agenda Item

Items to be presented by Dr. McNeill, Chairman:

- 3. Action Item Approval of DUR Board Meeting Minutes See Appendix A.
 - A. December 10, 2008 DUR Minutes Vote
 - B. December 11, 2008 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. McNeill, Chairman:

- 4. Update on DUR/MCAU Program See Appendix B.
 - A. Retrospective Drug Utilization Review for October 2008
 - B. Retrospective Drug Utilization Review Responses for August 2008
 - C. Medication Coverage Activity Audit for December 2008
 - D. Help Desk Activity Audit for December 2008

Items to be presented by Lynn Rambo-Jones, J.D., Dr. McNeill, Chairman:

5. Update on Supplemental Rebates

Items to be presented by Dr. Le, Dr. Chonlahan, Dr. McNeill, Chairman

- 6. Action Item Vote to Prior Authorize Toviaz® See Appendix C.
 - A. Product Summary
 - B. COP Recommendations
 - C. Utilization Review

Items to be presented by Dr. Le, Dr. McNeill, Chairman

7. Action Item – Vote to Prior Authorize Simcor® and Update Statin PBPA Category – See Appendix D.

A. COP Recommendations

Items to be presented by Dr. Moore, Dr. McNeill, Chairman

- 8. Action Item Vote to Prior Authorize Lamisil® Granules See Appendix E.
 - A. Product Summary
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Patel, Dr. McNeill, Chairman

- Action Item Annual Review of Ophthalmic Anti-Infective PBPA Category See Appendix F.
 - A. Current PA Criteria
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Le, Dr. McNeill, Chairman

- 10. Action Item Utilization Review of Asthma Medications and Annual Review of Brovana® See Appendix G.
 - A. Utilization Review of Anti-Asthmatics
 - B. Market Update
 - C. COP Recommendations
 - D. Annual Review of Brovana®

Items to be presented by Dr. Keast, Dr. McNeill, Chairman

11. Lock-In Report – See Appendix H.

Items to be presented by Dr. Graham, Dr. McNeill, Chairman

- 12. FDA and DEA Updates See Appendix I.
- 13. Future Business
 - A. Hydrocodone Utilization Review
 - B. Pediatric Anti-Ulcer Utilization Review
 - C. Annual Reviews
 - D. New Product Reviews
- 14. Adjournment